A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Abroad (travel likely)RecruitingPHASE3

Conditions

Hypothalamic Obesity · Multiple Pituitary Hormone Deficiency Genetic Form · Septo-Optic Dysplasia · Optic Nerve Hypoplasia · Childhood-onset Combined Pituitary Hormone Deficiency · Pituitary Stalk Interruption Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University of Alabama, Birmingham, Alabama, United States

  • Children's Hospital Colorado, Aurora, Colorado, United States

  • Lurie Children's Hospital, Chicago, Illinois, United States

  • Boston Children's Hospital, Boston, Massachusetts, United States

  • Children's Minnesota, Saint Paul, Minnesota, United States

  • Columbia University Irving Medical Center, New York, New York, United States

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

  • Seattle Children's Research Institute, Seattle, Washington, United States

  • UCL Great Ormond Street Institute of Child Health, London, Greater London, United Kingdom

  • Birmingham Women and Children's Hospital NHS Trust, Birmingham, West Midlands, United Kingdom

  • Hull Royal Infirmary, Hull, United Kingdom

Study leads
  • David Meeker, MD

    Study Chair

    Rhythm Pharmaceuticals, Inc.